Aprepitant is under clinical development by Hoth Therapeutics and currently in Phase II for Chemotherapy Effects. According to GlobalData, Phase II drugs for Chemotherapy Effects have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aprepitant’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Aprepitant is under development for the treatment of dermatological related side effects (rash and skin disorders) of erlotinib therapy in cancer patients. The drug candidate is administered by topical route. It acts by targeting neurokinin-1 (NK-1) receptor. It was under development for Alzheimer's disease.
Hoth Therapeutics overview
Hoth Therapeutics is engaged in clinical stage drug development related activities for producing new generation drugs, vaccines and therapies for dermatological disorders that in turn offers enhanced quality and healthy life for its patients suffering with atopic dermatitis, chronic wounds, psoriasis, asthma and acne related conditions. The company is headquartered in New York, the US.
For a complete picture of Aprepitant’s drug-specific PTSR and LoA scores, buy the report here.